吉西他滨联合卡铂或顺铂治疗晚期三阴乳腺癌的疗效研究

Efficacy of Gemcitabine Combined with Carboplatin or Cisplatin in the Treatment of Advanced Triple-negative Breast Cancer

目的探讨和分析吉西他滨联合卡铂或顺铂治疗晚期三阴乳腺癌的临床治疗效果。方法将2015年9月—2018年2月的住院患者中,方便选出三阴乳腺癌的晚期患者70例作为分析对象,GC组的给药吉西他滨和卡铂。GP组的给药吉西他滨和顺铂,均为每3周为1个周期。然后在治疗完全停止后,每间隔7~9周进行1次电话式的随访(除非患者离世或失访),依据RECIST实体瘤的有关疗效标准来对实际疗效进行对比。结果经治疗,在实施治疗的阶段内没有病例出现死亡,GP组以及GC组的有效率分别为68.57%(24/35)、71.43%(25/35);2组的有效率对比差异无统计学意义(χ~2=2.701,P>0.05),在肝毒性以及肾毒性方面,2组无明显区别。结论对晚期三阴乳腺癌患者,选择顺铂与吉西他滨二者配合使用的策略,具有确切疗效,与吉西他滨配合顺铂的有效程度较为相近。在实际应用上,可考虑患者的自身状况后,采取最佳的治疗策略。

Objective To investigate and analyze the clinical effects of gemcitabine combined with carboplatin or cisplatin in the treatment of advanced triple-negative breast cancer. Methods 70 patients with advanced stage of triple-negative breast cancer were convenient selected from the hospitalized patients from September 2015 to February 2018. The GC group received gemcitabine and carboplatin. The administration of gemcitabine and cisplatin in the GP group was 1 cycle every 3 weeks. Then, after the treatment was completely stopped, a telephone follow-up was performed every 7-9 weeks （unless the patient died or was lost）, and the actual efficacy was compared according to the relevant efficacy criteria of RECIST solid tumors. Results After treatment, no eases died during the treatment period. The effective rates of GP group and GC group were 68.57%（24/35） and 71.43%（25/35）, respectively. There was no significant difference in the efficiency of the two groups （X2=2.701,P〉0.05）. There was no significant difference between the two groups in terms of hepatotoxicity and nephrotoxicity. Conclusion For patients with advanced triple-negative breast cancer, the strategy of using cisplatin combined with gemcitabine has a definite curative effect, and the efficacy of gemcitabine in combination with cisplatin is similar. In practical applications, the best treatment strategy can be taken after considering the patient＇s own condition.